Credit Suisse and Cowen are joint bookrunners; JMP, Stifel to assist
By Devika Patel
Knoxville, Tenn., Sept. 20 - Bind Therapeutics, Inc. said it priced its $70.5 million initial public offering of stock with a $10.58 million greenshoe. The deal was announced Aug. 12.
The company will sell 4.7 million common shares at $15.00 apiece.
Credit Suisse (USA) LLC and Cowen and Co., LLC are the joint bookrunning managers.
Settlement is expected Sept. 25.
Proceeds will be used for development of BIND-014, working capital and general corporate purposes.
Based in Cambridge, Mass., the clinical-stage nanomedicine company is developing Accurins, which is designed to target specific cells or tissues and concentrate a therapeutic payload at the site of disease. The company intends to list its common stock on the Nasdaq under the symbol "BIND."
| Issuer: | Bind Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $70.5 million
|
| Greenshoe: | $10,575,000
|
| Shares: | 4.7 million
|
| Price: | $15.00
|
| Warrants: | No
|
| Bookrunners: | Credit Suisse (USA) LLC and Cowen and Co., LLC
|
| Co-managers: | Stifel Nicolaus & Co., Inc. and JMP Securities LLC
|
| Announcement date: | Aug. 12
|
| Pricing date: | Sept. 20
|
| Settlement date: | Sept. 25
|
| Stock exchange: | Nasdaq: BIND
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
